April 2024 Newsletter
New Animal Models
New Cell Models
News
Biocytogen highlights new preclinical animal models and antibody assets at? AACR Annual Meeting 2024
Promotions
Biocytogen Pharmacology Service Guarantee
In our commitment to providing unparalleled value to our clients, we are pleased to announce a Complimentary Overage Policy, Risk-Free Model Build Policy, and 100% Money-back Guarantee Policy.?
领英推荐
Upcoming Events
Bispecific ADCs are a growing trend in the ADC field, offering improved efficacy and safety for the treatment of heterogeneous solid tumors. Designing bsADCs requires careful selection of targets, and is not without challenges, including the ability to efficiently screen and assemble bsAbs for further conjugation. To facilitate bsADC development, Biocytogen established a bsADC platform, which harnesses:
In this webinar, Dr. W. Frank An will discuss the current landscape of bsADCs as a novel therapeutic modality, and provide an introduction to Biocytogen’s bsADC platform, highlighting recent progress of several of the company’s bsADC assets.
Event Date: Apr 24, 2024, 12:00 PM EDT | Event Location: Online
Join us at the Festival of Biologics USA 2024 from April 15-17 in San Diego, CA! Stop by booth #442 and learn about our BioMice and Renbiologics assets, ranging from preclinical animal models and pharmacology evaluation services to antibody assets for licensing. We will also have a poster on display on the second day of the event in the poster zone.
Event Date: April 15-17, 2024 | Event Location: San Diego, CA
Visit Our Bispecific Antibody Poster at IO Summit Europe 2024!
Biocytogen’s antibody Business Development & Licensing team is excited to attend the upcoming Immuno-Oncology Summit Europe 2024 conference, set to take place in London, UK, from April 23-25, 2024! During the event, our team will present a poster, titled “Fully human conditional agonist 4-1BB x CD40 bispecific antibody exhibits potent in vitro and in vivo efficacy”. Our novel 4-1BB x CD40 bispecific antibody (BCG021) significantly enhanced the in vivo?anti-tumor efficacy of anti-PD-1 monoclonal antibody therapy. Furthermore, preclinical studies in mouse models indicated a favorable safety profile for BCG021.
Bispecific antibodies offer novel therapeutic mechanisms, distinct from monotherapies and combination therapies. They offer conditional activation or precise targeting of the tumor microenvironment to mitigate systemic toxicity. Additionally, bispecific antibodies provide dual blockade abilities, effectively addressing drug resistance concerns.
To facilitate the development of bispecific antibodies, Biocytogen has developed RenLite? mice capable of generating fully human common light chain antibodies, which serve as building blocks for constructing Y-shaped bispecific antibodies. Using this strategy, we have developed numerous bispecific antibodies including, a CTLA-4 x OX40 bsAb for oncology and an OX40 biparatopic bsAb for autoimmune diseases.
We look forward to exploring partnership opportunities with you for our antibody-based assets or antibody discovery platforms! For questions, please contact [email protected].
Event Date: April 23-25, 2024 | Event Location: London, UK